Hepatitis B elimination in children of Slovenian origin born in Slovenia after the introduction of preventive strategies: The results of a national study
Article Category: Original scientific article
Data publikacji: 21 mar 2022
Zakres stron: 109 - 114
Otrzymano: 22 mar 2021
Przyjęty: 18 lut 2022
DOI: https://doi.org/10.2478/sjph-2022-0015
Słowa kluczowe
© 2022 National Institute of Public Health, Slovenia, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
With an estimated 257 million chronically infected persons worldwide, hepatitis B virus (HBV) infection still represents a major global public health problem, despite the long-term existence of highly effective hepatitis B prevention strategies, including the HBV vaccine (1, 2, 3). In Europe the average HBV prevalence has been estimated at 2%, whereas in highly endemic areas of Africa and the Pacific it is up to 22.7% (4). In Slovenia, HBV prevalence has been estimated at below 1% (5).
In 2016, the World Health Organization (WHO) adopted a strategy to eliminate HBV infection by 2030 and stated five core interventions: three doses of hepatitis B vaccination for children, a hepatitis B birth-dose to prevent perinatal transmission, blood and injection safety, harm reduction (syringe/needle set for people who inject drugs) and testing services/treatment (1, 6, 7, 8, 9). Since perinatal or early postnatal transmission represents the most significant source of chronic HBV infection (CHB) globally, in 2017 WHO recommended that all infants should receive their first dose of hepatitis B vaccine as soon as possible after birth (10). According to the WHO report, up until 2016 active immunization against hepatitis B had been included in the national programs of mandatory vaccination of children in 98% of member states (11). In 2015, global coverage with the three doses of hepatitis B vaccine in infancy reached 84%, while coverage with the initial birth dose was reported still to be low at 39% (1). In 2016 in the United States of America only 60.6% of newborns received the HBV vaccine (12).
In Slovenia, preventive vaccination against hepatitis B was included in the national program of mandatory vaccination of children in December 1997; children born after 1992 were vaccinated at the age of six, before entering elementary school, and from 2020 children are vaccinated against HBV at the age of 3 months (13).
Additionally, all the newborns of HBV surface antigen (HBsAg)-positive mothers receive specific human immune-globulins immediately after birth together with the first dose of HBV vaccine (14).
Mandatory screening of pregnant women for HBsAg was introduced in Slovenia in 1994 (15). According to the latest European Centre for Disease Prevention and Control (ECDC) data, antenatal screening for hepatitis B has been implemented in 23 out of 26 European countries; in the majority of reporting countries (8/13), screening coverage was ≥95% (16).
The aim of the present study was to analyze epidemiological characteristics of CHB in children in Slovenia after the introduction of mandatory HBV vaccination and mandatory screening of pregnant women for HBsAg with consecutive active and passive immunization of newborns of HBsAg-positive mothers.
All HBsAg-positive children 18 years of age or younger extracted from the central database totaling 1,729 persons from all regions of Slovenia who tested positive for HBsAg at the national reference laboratory for viral hepatitis (Laboratory for Molecular Microbiology and Diagnostics of Hepatitis and HIV/AIDS, Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana) between January 1997 and December 2010 were included in this study.
Available epidemiological and clinical characteristics were reviewed from the medical documentation at five hospitals responsible for the management of patients with viral hepatitis (University Medical Centers Ljubljana and Maribor, and General Hospitals in Celje, Novo Mesto, and Murska Sobota).
Origin was defined as “country, race, or social class of a person’s parents or ancestors” (17).
In all samples HBsAg and HBeAg were determined using the ARCHITECT Immunoassay analyzer (Abbott, Weisbaden, Germany) and HBV DNA viral load using the real-time polymerase chain reaction (RT-PCR) based Abbott RealTime HBV Test (Abbott). Viral load was categorized according to the clinical implications into three ranges: ≤ 2,000 IU/mL, 2,000-20,000 IU/mL and ≥ 20,000 IU/mL (18).
Associations were tested using univariate and multiple logistic regression, likelihood ratio or the Mann-Whitney U test, as appropriate. Possible time trends during the observation period were determined. No correction for multiple comparisons was made. Significance tests were two-sided. P-values ≤0.05 were considered statistically significant. Statistical analysis was performed using R program 3.1.1 and SPSS 23.0.
A total of 52 eligible children were included. Table 1 shows the baseline characteristics of the included children.
Demographic, epidemiological, clinical and virological characteristics of included children (N=52).
| % | |
|---|---|
| Female | 22 (42.3) |
| Male | 30 (57.7) |
| 13.3 (5.5; 0-18) | |
| Unknown | 8 (22.9) |
| Presence of HBV infection within the family | 24 (68.8) |
| Blood/blood products transfusion | 1 (2.9) |
| High-risk sexual behavior | 1 (2.9) |
| Surgical procedure in the past | 1 (2.9) |
| ≤ 0.56 | 14 (48.3) |
| > 0.56 | 15 (51.7) |
| Negative | 23 (57.5) |
| Positive | 17 (42.5) |
| < 2,000 | 9 (37.5) |
| 2,000–20,000 | 0 (0) |
| > 20,000 | 15 (62.5) |
HBV – hepatitis B virus, ALT – alanine aminotransferase, SD – standard deviation, IU – international units
A statistically significant association between the presence of HBeAg and a viral load above 20,000 IU/ml (p=0.001) was found. Table 2 presents the demographic, epidemiological, clinical and virological characteristics of the included children regarding presence/absence of HBeAg.
Demographic, epidemiological, clinical and virological characteristics of included children regarding presence/absence of hepatitis B virus e antigen (N=40).
| Domain | HBeAg-negative n (%) | HBeAg-negative n (%) | p- value |
|---|---|---|---|
| 23 (57.5) | 17 (42.5) | ||
| 9 (39.1) | 8 (47.1) | 0.616a | |
| 14 (60.9) | 9 (52.9) | ||
| 14 (0-18) | 17 (0-18) | 0.334c | |
| 17 (60.7) | 11 (39.3) | ||
| 4 (23.5) | 3 (27.3) | 0.824b | |
| 12 (70.6) | 6 (54.5) | 0.389b | |
| 1 (5.9) | 0 (0) | 0.312b | |
| 0 (0) | 1 (9.1) | 0.165b | |
| 0 (0) | 1 (9.1) | 0.165b | |
| 10 (66.7) | 2 (28.6) | ||
| 5 (33.3) | 5 (71.4) | 0.092b | |
| 8 (66.7) | 0 (0) | 0.001b | |
| 0 (0) | 0 (0) | ||
| 4 (33.3) | 8 (100) |
a=hi-square test; b=likelihood ratio test; c=Mann-Whitney U test
HBV – hepatitis B virus, ALT – alanine aminotransferase, HBeAg – hepatitis B virus e antigen, IU – international units
Out of the 52 children, 47 were of Slovenian origin. The oldest child of Slovenian origin included in the study was born in 1979. Altogether 41/52 (78.8%) children were born before or in 1994, 39 of Slovenian origin and two of foreign parents. There were 11/52 (21.1%) children born after 1994, eight Slovenians and three foreigners. The difference in the proportion of children of Slovenian origin born before 1994 and after 1994 was statistically significant (p=0.039). Children of Slovenian origin born after 1994 with CHB were born in 1996, 1998, 2003, and the last chronically infected child in 2004 (Table 3). Unfortunately, we found clinical data for three children only who are still followed. Two of them have active CHB and one seroconverted. Interestingly, the last chronically infected child was born to a father who acquired HBV infection while vaccinated in the Yugoslav National Army (YNA) (19).
Number of children of Slovenian origin by year of birth (N=47).
| YEAR OF BIRTH | NUMBER OF CHILDREN |
|---|---|
| 1 | |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 3 | |
| 3 | |
| 2 | |
| 4 | |
| 2 | |
| 2 | |
| 6 | |
| 0 | |
| 0 | |
| 0 | |
| 2 | |
| 0 | |
| 5 | |
| 0 | |
| 1 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 1 | |
| 1 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 47 |
A statistically significant negative linear trend (p=0.019) was present in the annual number of diagnosed children in the period 1997–2010, as shown in Figure 1, while in the same period there was no linear trend present in the entire population (p=0.978) (Figure 2).
Figure 1
The annual number of newly registered hepatitis B virus chronically infected children in the studied period 1997–2010 (N=52).
Figure 2
The annual number of newly registered hepatitis B virus chronically infected persons in the studied period 1997–2010 (N=1.729).
To the best of our knowledge this is the first study describing the epidemiological characteristics of children chronically infected with HBV in Slovenia. The most common risk factor among children included in our study was “presence of HBV infection within the family” (68.8%), as has been reported in other European countries (20). In countries with low HBV prevalence the most common routes of childhood infection are perinatal transmission or transmission in early childhood (10). Consequently, antenatal screening, antiviral prophylaxis in pregnancy and early HBV vaccination are vital for preventing HBV infection (21, 22).
Our results have shown that mandatory vaccination of children and screening of pregnant women for HBsAg with consecutive immunization of newborns of HBsAg positive mothers significantly reduced the incidence of CHB among children born in Slovenia. To the best of our knowledge, currently there are only four children with CHB in follow-up at the main Slovenian hospital, University Medical Center Ljubljana (UMCL), none of them having been born in Slovenia (they were born in China, Ghana, Ukraine and Thailand, respectively) (Breda Zakotnik, MD, B.Sc, personal communication, unpublished data).
Similar reports on the effectiveness of the HBV child vaccination come from Bulgaria (23), Taiwan (24) and China (25). There are also reports on protection from HBsAg carriage after hepatitis B immunization in the general population (26).
An HBV DNA viral load greater than 20,000 IU/ml was found in a significant proportion of HBeAg-positive children. This finding is consistent with the natural course of HBV infection in the Mediterranean region (27, 28). Our children and young adults are still in phase two of the natural course of the disease (HBeAg-positive chronic hepatitis) (18), for which a high HBV DNA viral load is characteristic.
The main strength of our study is its national coverage, while a major limitation is that some statistical analysis had to be performed in smaller subgroups due to lack of data. There is also a potential chance that some children and pregnant women were never diagnosed at the national reference laboratory for viral hepatitis, but at Blood Transfusion Centers of Slovenia. In further research, which is currently in progress, we will focus on a determination of the prevalence of HBsAg-positive pregnant women in Slovenia in the past 20 years and try to obtain data on chemoprophylaxis of pregnant women and the proportion of newborns of HBsAg-positive mothers who received passive and active immunization, with the aim of updating national guidelines for the treatment of HBsAg-positive pregnant women and their newborns.
Our study showed that prevention strategies adopted in the mid-nineties – mandatory vaccination of children against hepatitis B and mandatory HBsAg screening of pregnant women – have resulted in complete elimination of CHB in children of Slovenian origin born in Slovenia after 2004. We sincerely hope that elimination of CHB in children in Slovenia will soon be followed by the same achievement in other countries in the region, or at least that we can show the way forward to achieving this goal.